Advertisement

Index by Author

May 1987; 36 (5)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Anderson, J H, Jr

    • Involvement of endogenous opiates in glucose-stimulated hyperinsulinism of canine endotoxin shock. Inhibition by naloxone. Diabetes May 1987 36:585-591; doi:10.2337/diabetes.36.5.585

  2. Aurell, M

    • Advanced diabetic glomerulopathy. Quantitative structural characterization of nonoccluded glomeruli. Diabetes May 1987 36:612-619; doi:10.2337/diabetes.36.5.612

B

  1. Bar-Oz, B

    • Somatostatin impairs clearance of exogenous insulin in humans. Diabetes May 1987 36:673-677; doi:10.2337/diabetes.36.5.673

  2. Beltz, W F

    • Treatment with artificial beta-cell decreases very-low-density lipoprotein triglyceride synthesis in type I diabetes. Diabetes May 1987 36:661-666; doi:10.2337/diabetes.36.5.661

  3. Bendtzen, K

    • Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes May 1987 36:641-647; doi:10.2337/diabetes.36.5.641

  4. Bottazzo, G F

    • Progress toward standardization of cytoplasmic islet cell-antibody assay. Diabetes May 1987 36:578-584; doi:10.2337/diabetes.36.5.578

C

  1. Caro, J F

    • Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes May 1987 36:620-625; doi:10.2337/diabetes.36.5.620

  2. Carroll, P B

    • Treatment with artificial beta-cell decreases very-low-density lipoprotein triglyceride synthesis in type I diabetes. Diabetes May 1987 36:661-666; doi:10.2337/diabetes.36.5.661

  3. Cerasi, E

    • Somatostatin impairs clearance of exogenous insulin in humans. Diabetes May 1987 36:673-677; doi:10.2337/diabetes.36.5.673

  4. Chayoth, R

    • Insulin binding and glucose transport in adipocytes in neonatal streptozocin-injected rat model of diabetes mellitus. Diabetes May 1987 36:654-660; doi:10.2337/diabetes.36.5.654

  5. Chiasson, J L

    • Therapeutic modulation of growth-promoting activity in platelets from diabetics. Diabetes May 1987 36:667-672; doi:10.2337/diabetes.36.5.667

  6. Creutzfeldt, W

    • Inhibition of glycogenolysis and glycogen phosphorylase by insulin and proinsulin in rat hepatocyte cultures. Diabetes May 1987 36:551-555; doi:10.2337/diabetes.36.5.551

D

  1. D'Onofrio, F

    • Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Diabetes May 1987 36:566-570; doi:10.2337/diabetes.36.5.566

  2. Deen, W M

    • Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes May 1987 36:556-565; doi:10.2337/diabetes.36.5.556

  3. Disilvio, L

    • Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes May 1987 36:632-640; doi:10.2337/diabetes.36.5.632

  4. Doré, E

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

  5. Draznin, B

    • Cytosolic free-calcium concentrations in normal pancreatic islet cells. Effect of secretagogues and somatostatin. Diabetes May 1987 36:571-577; doi:10.2337/diabetes.36.5.571

  6. Dunn, F L

    • Treatment with artificial beta-cell decreases very-low-density lipoprotein triglyceride synthesis in type I diabetes. Diabetes May 1987 36:661-666; doi:10.2337/diabetes.36.5.661

F

  1. Fantus, I G

    • Insulin binding and glucose transport in adipocytes in neonatal streptozocin-injected rat model of diabetes mellitus. Diabetes May 1987 36:654-660; doi:10.2337/diabetes.36.5.654

  2. Featherbe, D

    • Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes May 1987 36:632-640; doi:10.2337/diabetes.36.5.632

  3. Ferré, P

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

  4. Flickinger, E G

    • Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes May 1987 36:620-625; doi:10.2337/diabetes.36.5.620

  5. Frankel, B J

    • Abnormalities in glucose-stimulated insulin release, 45Ca uptake, and 86Rb efflux in diabetic Chinese hamster islets. Diabetes May 1987 36:648-653; doi:10.2337/diabetes.36.5.648

  6. Franks, D J

    • Therapeutic modulation of growth-promoting activity in platelets from diabetics. Diabetes May 1987 36:667-672; doi:10.2337/diabetes.36.5.667

G

  1. Girard, J

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

  2. Gleichmann, H

    • Progress toward standardization of cytoplasmic islet cell-antibody assay. Diabetes May 1987 36:578-584; doi:10.2337/diabetes.36.5.578

  3. Grose, M

    • Insulin binding and glucose transport in adipocytes in neonatal streptozocin-injected rat model of diabetes mellitus. Diabetes May 1987 36:654-660; doi:10.2337/diabetes.36.5.654

  4. Gundersen, H J

    • Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes May 1987 36:597-601; doi:10.2337/diabetes.36.5.597
    • Advanced diabetic glomerulopathy. Quantitative structural characterization of nonoccluded glomeruli. Diabetes May 1987 36:612-619; doi:10.2337/diabetes.36.5.612

H

  1. Hamet, P

    • Therapeutic modulation of growth-promoting activity in platelets from diabetics. Diabetes May 1987 36:667-672; doi:10.2337/diabetes.36.5.667

  2. Hansen, B S

    • Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes May 1987 36:641-647; doi:10.2337/diabetes.36.5.641

  3. Hartmann, H

    • Inhibition of glycogenolysis and glycogen phosphorylase by insulin and proinsulin in rat hepatocyte cultures. Diabetes May 1987 36:551-555; doi:10.2337/diabetes.36.5.551

  4. Hawa, M I

    • Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes May 1987 36:632-640; doi:10.2337/diabetes.36.5.632

  5. Hsieh, S D

    • Reduced urinary insulin clearance in patient with abnormal insulinemia. Diabetes May 1987 36:602-606; doi:10.2337/diabetes.36.5.602

I

  1. Ipp, E

    • Somatostatin impairs clearance of exogenous insulin in humans. Diabetes May 1987 36:673-677; doi:10.2337/diabetes.36.5.673

  2. Iwamoto, Y

    • Reduced urinary insulin clearance in patient with abnormal insulinemia. Diabetes May 1987 36:602-606; doi:10.2337/diabetes.36.5.602

J

  1. Jackson, R A

    • Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes May 1987 36:632-640; doi:10.2337/diabetes.36.5.632

  2. Jakobsen, J

    • Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes May 1987 36:597-601; doi:10.2337/diabetes.36.5.597

  3. Jaspan, J B

    • Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes May 1987 36:632-640; doi:10.2337/diabetes.36.5.632

  4. Jeanrenaud, B

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

  5. Jones, H W, 3rd

    • Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes May 1987 36:556-565; doi:10.2337/diabetes.36.5.556

  6. Jungermann, K

    • Inhibition of glycogenolysis and glycogen phosphorylase by insulin and proinsulin in rat hepatocyte cultures. Diabetes May 1987 36:551-555; doi:10.2337/diabetes.36.5.551

  7. Jørgensen, D W

    • Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes May 1987 36:641-647; doi:10.2337/diabetes.36.5.641

K

  1. Kinebanyan, M F

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

  2. Klaff, L J

    • Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes May 1987 36:592-596; doi:10.2337/diabetes.36.5.592

  3. Kurtz, A B

    • Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes May 1987 36:632-640; doi:10.2337/diabetes.36.5.632

  4. Kuzuya, T

    • Reduced urinary insulin clearance in patient with abnormal insulinemia. Diabetes May 1987 36:602-606; doi:10.2337/diabetes.36.5.602

L

  1. Lecavalier, L

    • Therapeutic modulation of growth-promoting activity in platelets from diabetics. Diabetes May 1987 36:667-672; doi:10.2337/diabetes.36.5.667

  2. Lefèbvre, P J

    • Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Diabetes May 1987 36:566-570; doi:10.2337/diabetes.36.5.566

  3. Leitner, J W

    • Cytosolic free-calcium concentrations in normal pancreatic islet cells. Effect of secretagogues and somatostatin. Diabetes May 1987 36:571-577; doi:10.2337/diabetes.36.5.571

  4. Leturque, A

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

M

  1. Mandrup-Poulsen, T

    • Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes May 1987 36:641-647; doi:10.2337/diabetes.36.5.641

  2. Marliss, E B

    • Insulin binding and glucose transport in adipocytes in neonatal streptozocin-injected rat model of diabetes mellitus. Diabetes May 1987 36:654-660; doi:10.2337/diabetes.36.5.654

  3. Matsuda, A

    • Reduced urinary insulin clearance in patient with abnormal insulinemia. Diabetes May 1987 36:602-606; doi:10.2337/diabetes.36.5.602

  4. Meelheim, D

    • Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes May 1987 36:620-625; doi:10.2337/diabetes.36.5.620

  5. Merrill, G A

    • Involvement of endogenous opiates in glucose-stimulated hyperinsulinism of canine endotoxin shock. Inhibition by naloxone. Diabetes May 1987 36:585-591; doi:10.2337/diabetes.36.5.585

  6. Myers, B D

    • Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes May 1987 36:556-565; doi:10.2337/diabetes.36.5.556

N

  1. Nerup, J

    • Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes May 1987 36:641-647; doi:10.2337/diabetes.36.5.641

  2. Nesher, R

    • Somatostatin impairs clearance of exogenous insulin in humans. Diabetes May 1987 36:673-677; doi:10.2337/diabetes.36.5.673

  3. Nielsen, J H

    • Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes May 1987 36:641-647; doi:10.2337/diabetes.36.5.641

  4. Nyberg, G

    • Advanced diabetic glomerulopathy. Quantitative structural characterization of nonoccluded glomeruli. Diabetes May 1987 36:612-619; doi:10.2337/diabetes.36.5.612

O

  1. O'Dea, L

    • Insulin binding and glucose transport in adipocytes in neonatal streptozocin-injected rat model of diabetes mellitus. Diabetes May 1987 36:654-660; doi:10.2337/diabetes.36.5.654

  2. Olefsky, J M

    • Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes May 1987 36:607-611; doi:10.2337/diabetes.36.5.607

  3. Osterby, R

    • Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes May 1987 36:597-601; doi:10.2337/diabetes.36.5.597
    • Advanced diabetic glomerulopathy. Quantitative structural characterization of nonoccluded glomeruli. Diabetes May 1987 36:612-619; doi:10.2337/diabetes.36.5.612

P

  1. Paolisso, G

    • Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Diabetes May 1987 36:566-570; doi:10.2337/diabetes.36.5.566

  2. Passariello, N

    • Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Diabetes May 1987 36:566-570; doi:10.2337/diabetes.36.5.566

  3. Pénicaud, L

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

  4. Picon, L

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

  5. Pories, W J

    • Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes May 1987 36:620-625; doi:10.2337/diabetes.36.5.620

  6. Prager, R

    • Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes May 1987 36:607-611; doi:10.2337/diabetes.36.5.607

  7. Probst, I

    • Inhibition of glycogenolysis and glycogen phosphorylase by insulin and proinsulin in rat hepatocyte cultures. Diabetes May 1987 36:551-555; doi:10.2337/diabetes.36.5.551

  8. Prowse, S J

    • Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes May 1987 36:641-647; doi:10.2337/diabetes.36.5.641

S

  1. Sakura, H

    • Reduced urinary insulin clearance in patient with abnormal insulinemia. Diabetes May 1987 36:602-606; doi:10.2337/diabetes.36.5.602

  2. Scheen, A

    • Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Diabetes May 1987 36:566-570; doi:10.2337/diabetes.36.5.566

  3. Schwartz, H C

    • Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes May 1987 36:556-565; doi:10.2337/diabetes.36.5.556

  4. Sehlin, J

    • Abnormalities in glucose-stimulated insulin release, 45Ca uptake, and 86Rb efflux in diabetic Chinese hamster islets. Diabetes May 1987 36:648-653; doi:10.2337/diabetes.36.5.648

  5. Sgambato, S

    • Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels. Diabetes May 1987 36:566-570; doi:10.2337/diabetes.36.5.566

  6. Sidenius, P

    • Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes May 1987 36:597-601; doi:10.2337/diabetes.36.5.597

  7. Sim, B M

    • Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes May 1987 36:632-640; doi:10.2337/diabetes.36.5.632

  8. Sinai, Y

    • Somatostatin impairs clearance of exogenous insulin in humans. Diabetes May 1987 36:673-677; doi:10.2337/diabetes.36.5.673

  9. Sinha, M K

    • Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes May 1987 36:620-625; doi:10.2337/diabetes.36.5.620

  10. Spinas, G A

    • Islet cytotoxicity of interleukin 1. Influence of culture conditions and islet donor characteristics. Diabetes May 1987 36:641-647; doi:10.2337/diabetes.36.5.641

  11. Sugimoto, H

    • Therapeutic modulation of growth-promoting activity in platelets from diabetics. Diabetes May 1987 36:667-672; doi:10.2337/diabetes.36.5.667

  12. Sussman, K E

    • Cytosolic free-calcium concentrations in normal pancreatic islet cells. Effect of secretagogues and somatostatin. Diabetes May 1987 36:571-577; doi:10.2337/diabetes.36.5.571

T

  1. Taborsky, G J, Jr

    • Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes May 1987 36:592-596; doi:10.2337/diabetes.36.5.592

  2. Terretaz, J

    • Development of obesity in Zucker rats. Early insulin resistance in muscles but normal sensitivity in white adipose tissue. Diabetes May 1987 36:626-631; doi:10.2337/diabetes.36.5.626

  3. Tomlanovich, S

    • Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes May 1987 36:556-565; doi:10.2337/diabetes.36.5.556

W

  1. Wallace, P

    • Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes May 1987 36:607-611; doi:10.2337/diabetes.36.5.607

Y

  1. Yale, J F

    • Insulin binding and glucose transport in adipocytes in neonatal streptozocin-injected rat model of diabetes mellitus. Diabetes May 1987 36:654-660; doi:10.2337/diabetes.36.5.654

  2. Yamamoto, R

    • Reduced urinary insulin clearance in patient with abnormal insulinemia. Diabetes May 1987 36:602-606; doi:10.2337/diabetes.36.5.602

  3. Yoshioka, N

    • Reduced urinary insulin clearance in patient with abnormal insulinemia. Diabetes May 1987 36:602-606; doi:10.2337/diabetes.36.5.602

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement